Prevalence of Sarcopenia in Stroke Patients (NCT07492849) | Clinical Trial Compass
CompletedNot Applicable
Prevalence of Sarcopenia in Stroke Patients
Taiwan80 participantsStarted 2025-05-05
Plain-language summary
The goal of this observational study is to analyze the characteristics of sarcopenia-related variables in post-acute and chronic stroke patients using various clinical measurement tools. The study also aims to examine the differences in these variables based on age groups (40-65 years and \>65 years), sex, and stroke severity.
The main questions it aims to answer are:
What are the differences in sarcopenia prevalence and related indicators between post-acute care and chronic stroke patients? How do age, sex, and stroke severity affect these sarcopenia-related measurements?
Participants will include stroke patients aged 40 and older with adequate cognitive and physical function to complete sarcopenia screening and questionnaires. They will be divided into two groups:
Group 1: Chronic stroke patients (n ≥ 75) Group 2: Post-acute care stroke patients (n ≥ 25)
All participants will undergo both objective and subjective assessments, including:
Objective assessments: Body composition, quadriceps strength, quadriceps and gastrocnemius muscle thickness via ultrasound, calf circumference, dominant hand grip strength, walking speed, SARC-F questionnaire, and the Mini Nutritional Assessment.
Subjective assessment: EQ-5D health-related quality of life questionnaire. The collected data will be analyzed to compare the prevalence and characteristics of sarcopenia between the two stroke groups and across different subgroups by age and sex.
Who can participate
Age range
40 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Both ischemic and hemorrhagic strokes are included. 1.1 Definition of chronic stroke patients (Group 1): Patients whose last stroke occurred more than one year prior.
.2 Definition of post-acute care (PAC) stroke patients (Group 2): Patients whose last stroke occurred at least 14 days prior, have been assessed by a neurologist as eligible for transfer to the PAC program, and are admitted to a PAC ward.
. Patients with sufficient cognitive and physical ability to complete sarcopenia-related assessments (e.g., body composition, grip strength, walking speed) and the Mini Nutritional Assessment, as judged by the principal investigator.
. Patients who provide informed consent after being fully informed. 3.1 Group 1 (chronic stroke patients): Consent must be obtained directly from the patient.
.2 Group 2 (PAC stroke patients): If the patient has cognitive impairment during the PAC phase, consent may be obtained from a family member or legal representative after they have been fully informed. -
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Appendicular Skeletal Muscle Mass Index
Timeframe: at enrollment
2
Handgrip strength
Timeframe: at enrollment
3
Gait speed
Timeframe: at enrollment
Trial details
NCT IDNCT07492849
SponsorCishan Hospital, Ministry of Health and Welfare
. Patients with lower limb neurological, muscular, or skeletal injuries or disorders within six months prior to enrollment.
. Patients with severe cardiopulmonary diseases or other neurological conditions requiring oxygen therapy.
. Patients who, within one month prior to the study, have experienced major infections requiring hospitalization and antibiotic administration or other major illnesses requiring invasive treatment (e.g., cardiac catheterization). -